Hereditary Angioedema (HAE) Highlights from ACAAI 2021 Annual Meeting
Jointly Provided by
Supported by an educational grant from BioCryst.
Start date: February 15, 2022
End date: February 15, 2023
Estimated time to complete: 0.25 hours
NO LONGER AVAILABLE FOR CREDIT
Activity Description
This accredited CME activity provides a summary of the latest information about hereditary angioedema (HAE) that was presented at the American College of Allergy, Asthma, & immunology 2021 Annual Scientific Meeting (ACAAI 2021). Since the Covid-19 pandemic limited the ability for specialists to attend ACAAI 2021 and discuss this latest research, this program provides an expert review of the most clinically-relevant information on HAE presented during the meeting.
HAE is a rare genetic disease that results in immunologic attacks that can be life threatening. Since HAE requires a team approach to care, this program will also benefit clinicians who may be involved in the care of patients with HAE but who don’t typically attend the ACAAI annual meeting.
Activity Faculty
Jonathan Bernstein, MD
Professor of Medicine
University of Cincinnati
Partner, Bernstein Allergy Group
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in pulmonology, immunology, internal medicine, general practice, and emergency medicine. Other members of the care team may also participate.
After participating in the activity, learners should be better able to:
- Describe the latest research being presented to better manage HAE and its clinical relevance
Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures are as follows:
Faculty Educators
Dr. Bernstein discloses the following financial relationships:
- Advisory Board/Consultant: Takeda/Shire, CSL Behring, Pharming, BioCryst, KalVista, Ionis, BioMarin, Intellia, Pharvaris
- Shareholder: Pfizer, Abbott
- Grant/Research Support: Takeda/Shire, CSL Behring, Pharming, BioCryst, KalVista, Ionis, BioMarin
- Speaker’s Bureau: Takeda/Shire, CSL Behring, Pharming, BioCryst
Planners for this activity have no relevant financial relationships with any commercial interests.
This activity will review off-label or investigational information.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.
Hardware/Software Requirements
Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Privacy
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm. For more information about CheckRare’s privacy policy, please access https://checkrare.com/privacy/
Contact
For any questions, please contact: CEServices@academycme.org
Copyright
© 2022. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
Hereditary Angioedema (HAE) Highlights from ACAAI 2021 Annual Meeting
Helpful Links
Advocacy Groups
US Hereditary Angioedema Association
https://www.haea.org/
HAE International
https://haei.org/
Guidelines
US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema
https://www.jaci-inpractice.org/article/S2213-2198(20)30878-3/fulltext
ACAAI 2021 Abstracts: Hereditary Angioedema
Anderson J et al. Consistently low hereditary angioedema (HAE) attacks rates observed in US patients treated with berotralstat. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S14.
Reidl M et al. Berotralstat demonstrates low hereditary angioedema attack rates in patients switching from injectable prophylaxis. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S26- 27.
Bernstein J et al. Improved patient satisfaction with berotralstat in patients switching from injectable hereditary angioedema (HAE) prophylactic treatments. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S27.
Kinaciyan T et al. Sustained reduction in hereditary angioedema attack rates following switch to berotralstat: subgroup analysis from APEX-2. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S29.
Riedl M et al. Attack-free status in the HELP OLE: long-term lanadelumab prophylactic treatment for 12 months or longer. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S29.
Cohn D et al. A phase 2 study evaluating an antisense oligonucleotide to prekallikrein in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S4.
Bernstein J et al. On-demand oral treatment with KVD900 for HAE attacks achieved rapid exposure and improves patient outcomes. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S4-5.
Yea C et al. Relationship between PGI-C scale and other PROs in KVD900 trial in HAE. TRIAL IN HAE. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S29.
Bista P et al. QLS-215 is a long-acting monoclonal antibody plasma kallikrein inhibitor for the potential treatment of HAE. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S28.
Kim M et al. Worsening angioedema in a patient with a diagnosis of hereditary angioedema (HAE). Ann Allergy Asthma Immunol. 2021; 127 (suppl): S81-82.
Jones D et al. Joint pain: a rare symptom in patients with hereditary angioedema with normal C1- INH. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S82.
Shapero M et al. An unusual presentation of hereditary angioedema. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S83.
Grohman R et al. Autoimmune lymphoproliferative syndrome presenting as recurrent fevers in hereditary angioedema with normal C1 inhibitor. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S84.
Imam K et al. hereditary angioedema presenting as abdominal pain. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S84-85.
Iman et al. A novel SERPING1 mutation in a case of hereditary angioedema. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S85.
Owens J, Maples K. Blepharochalasis: a hereditary angioedema masquerader. Recurrent angioedema in a 12 year-old African American male. Ann Allergy Asthma Immunol. 2021; 127 (suppl): S85-86.
Jointly Provided by
Supported by an educational grant from BioCryst.
Start date: February 15, 2022
End date: February 15, 2023
Estimated time to complete: 0.25 hours
NO LONGER AVAILABLE FOR CREDIT
Activity Description
This accredited CME activity provides a summary of the latest information about hereditary angioedema (HAE) that was presented at the American College of Allergy, Asthma, & immunology 2021 Annual Scientific Meeting (ACAAI 2021). Since the Covid-19 pandemic limited the ability for specialists to attend ACAAI 2021 and discuss this latest research, this program provides an expert review of the most clinically-relevant information on HAE presented during the meeting.
HAE is a rare genetic disease that results in immunologic attacks that can be life threatening. Since HAE requires a team approach to care, this program will also benefit clinicians who may be involved in the care of patients with HAE but who don’t typically attend the ACAAI annual meeting.
Activity Faculty
Jonathan Bernstein, MD
Professor of Medicine
University of Cincinnati
Partner, Bernstein Allergy Group
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in pulmonology, immunology, internal medicine, general practice, and emergency medicine. Other members of the care team may also participate.
After participating in the activity, learners should be better able to:
- Describe the latest research being presented to better manage HAE and its clinical relevance
Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures are as follows:
Faculty Educators
Dr. Bernstein discloses the following financial relationships:
- Advisory Board/Consultant: Takeda/Shire, CSL Behring, Pharming, BioCryst, KalVista, Ionis, BioMarin, Intellia, Pharvaris
- Shareholder: Pfizer, Abbott
- Grant/Research Support: Takeda/Shire, CSL Behring, Pharming, BioCryst, KalVista, Ionis, BioMarin
- Speaker’s Bureau: Takeda/Shire, CSL Behring, Pharming, BioCryst
Planners for this activity have no relevant financial relationships with any commercial interests.
This activity will review off-label or investigational information.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.
Hardware/Software Requirements
Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Privacy
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm. For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/
Contact
For any questions, please contact: CEServices@academycme.org
Copyright
© 2022. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
